Unable to display view head.php file not found.
This Figure summarizes the principal efficacy and safety endpoint results with rivaroxaban for prophylactic anticoagulation in patients with nonvalvular AFib.
Reiffel JA. Am J Med 2013; 126: 00-00.
[97] Patel MR, Mahaffey KW, Garg J, et al; the ROCKET AF Steering Committee, for the ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-891.